ClinicalTrials.gg
Active, not recruitingNCT04486755Updated Nov 5, 2026

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

A Phase 1 interventional study of Hypofractionated Radiation Therapy in Prostate Cancer and Prostate Adenocarcinoma, sponsored by University of Maryland, Baltimore. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Maryland, Baltimore · Phase 1, Interventional, and Treatment

How we know

Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore — 1 open to participants now, 4 under way, none of them phase 3. Prostatic Neoplasms · University of Maryland, Baltimore.

Planned enrollment
7th of 10
18 · median 27
Started
2020
with 1 other
Phase 1
2 of 14
none open now
Registered
10th of 14
by date

Among the 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 2 in phase 1, and was the 10th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore, or all of them as a file.
02

Study summary

A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate that have been designed to incrementally increased the biological equivalent dose (BED) to prostate cancer, while maintaining a constant BED to normal tissue toxicity.

Read the detailed description

Outcomes for patients with unfavorable intermediate-risk and high-risk prostate cancer (PC) have been historically poor and are now known to require multimodality treatment. A standard non-surgical treatment option for patients with localized, intermediate and high-risk PC is radiation therapy (RT) in combination with short- or long-term androgen deprivation therapy (ADT).

The benefit of pelvic nodal RT in this setting is unclear, previous studies have been equivocal. There is a growing body of evidence to demonstrate that use of hypofractionated (HypoFx) RT may be a safe method for increasing the dose of RT, while also decreasing normal tissue toxicity.

03

Conditions studied

  • Prostate Cancer
  • Prostate Adenocarcinoma

Browse trials for

Keywords

  • Prostate
  • Hypofractionated Radiation Therapy
  • Prostate Cancer
  • Radiotherapy
  • Proton Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient age is ≥ 18 years
  2. Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration.
  3. Patient's with intermediate to high risk prostate cancer and must be recommended to undergo pelvic as well as prostatic irradiation.
  4. History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration.
  5. Clinically negative lymph nodes as established by imaging (pelvic ± abdominal CT or MR), (but not by nodal sampling, or dissection) within 120 days prior to registration.

    • Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.5 cm.
  6. No evidence of bone (M0) on bone scan within 120 days prior to registration.

    • Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative for metastasis.
  7. Baseline serum PSA value performed within 12 weeks (90 days) prior to registration.
  8. Performance Status 0-1
  9. Patient must be able to provide study specific prior to study entry.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of distant
  2. Regional lymph node involvement
  3. Previous radical surgery (prostatectomy), cryosurgery, or HIFU (High-intensity focused ultrasound) for prostate cancer
  4. Previous pelvic irradiation or prostate brachytherapy
  5. Planned prostate brachytherapy boost
  6. Previous or concurrent cytotoxic chemotherapy for prostate cancer
  7. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
  8. Patients are excluded if they have a history of disease that, in the opinion of the treating physician would be a to pelvic radiation (e.g., active systemic lupus, progressive scleroderma)
  9. Patients receiving full-dose anticoagulation or clopidogrel

    • Patients taking 81 mg Aspirin po daily may are still eligible for the study
  10. Patients with a history of prior small bowel ulceration
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 20 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.

    Radiation: Hypofractionated Radiation Therapy

  • Experimental
    Dose Level 2

    Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 16 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.

    Radiation: Hypofractionated Radiation Therapy

  • Experimental
    Dose Level 3

    Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 12 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.

    Radiation: Hypofractionated Radiation Therapy

Interventions

  • RadiationHypofractionated Radiation Therapy

    All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.

06

What researchers measure

Primary outcomes

  1. HypoFx RT schedule that results in <33% acute dose-limiting toxicity with accelerated, HypoFx pelvic nodal RT

    The frequency of all observed acute GI, GU, hematologic, and neurologic dose limiting toxicities by CTCAE v5 grade will be tabulated. DLT is defined as treatment-related: Grade ≥3 GI (small bowel or rectal) toxicity, Grade ≥3 GU toxicity, Grade ≥3 hematologic, Grade ≥3 neurologic toxicity, or any grade 5 treatment-related adverse events.

    Time frame: Within 90 days of completing RT

Secondary outcomes

  1. Frequency of acute and late GI, GU, hematologic, and neurologic toxicity for each dose cohort

    The frequency of the maximum grade acute (within 90 days completing RT) and late (occurring \> 90 days from treatment) GI (small bowel and rectal), GU, hematologic, and neurologic toxicities at 3-months, 6 months, 1-year and 2 years for each dose cohort using National Cancer Institute Common Terminology Criteria v.5.0 (NCI CTCAE v5).

    Time frame: Acute (within 90 days completing RT), Late (occurring > 90 days from treatment), 3-months, 6 months, 1-year and 2 years

  2. Dose volume histogram (DVH) parameters

    A dose-volume histogram is a histogram relating radiation dose to tissue volume in radiation therapy planning.

    Time frame: Within 90 days of completing RT

  3. Evaluate the duration of biochemical progression-free survival

    The duration of bPFS will be measured from the end of RT until either PSA recurrence or death due to any cause and summarized for the expanded cohort of patients treated at the maximum total dose (MTD). PSA recurrence is defined by the Phoenix definition of biochemical failure (PSA nadir + 2 ng/mL).

    Time frame: 2 years after completing RT

  4. Patient Reported Outcomes (PROs) related to urinary and bowel function

    Quality of life will be assessed with the validated Expanded Prostate Cancer Index Composite (EPIC) questionnaire.

    Time frame: 1 month after completion of treatment, every 3 months for year 1, and every 6 months during Year 2

  5. Patient Reported Outcomes (PROs) related to urinary function

    The International Prostate System Score (IPSS) questionnaire will be used for urinary function.

    Time frame: 1 month after completion of treatment, every 3 months for year 1, and every 6 months during Year 2

  6. Patient Reported Outcomes (PROs) related to urinary and bowel function

    The PRO-CTCAE questionnaire measures patient-reported bowel, urinary and sexual function.

    Time frame: 1 month after completion of treatment, every 3 months for year 1, and every 6 months during Year 2

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2027, 85 months after the start.

Of 243 non-industry phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 76. This study's planned 85 months is above that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Aug 2026 → Dec 2027 and completion Aug 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2020
First posted
Jul 27, 2020
StartActual
Nov 19, 2020
Primary completionEst.
Dec 2027was Aug 2026
CompletionEst.
Dec 2028was Aug 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Dec 2027
Nov 5, 2026
Study completion
Aug 2027→Dec 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Aug 2026→Dec 2027
    Study completion Aug 2027→Dec 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04486755
Responsible party
Department of Radiation Oncology (Principal Investigator, University of Maryland, Baltimore) — Principal investigator
First posted
Jul 27, 2020
Start date
Nov 19, 2020
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion